Three Small Biotech Firms Announce Reverse Stock Splits on the Same Day

Three small-cap biopharmaceutical companies announced reverse stock splits on October 16, 2026, each at different ratios and effective dates. Moleculin Biotech announced a 1-for-20 reverse split, the most aggressive of the three, with shares sliding on the news. Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company based in San Diego, announced a 1-for-7 split effective October 20, 2026, with trading to begin on a post-split basis at the open that day. Azitra, Inc. (NASDAQ: AZTR) announced a 1-for-10 reverse split effective October 26, 2026, with shares continuing to trade under the AZTR ticker on a split-adjusted basis.

Reverse stock splits reduce the number of shares outstanding while proportionally increasing the per-share price, and are commonly used by companies trading at low prices to meet minimum bid requirements for continued exchange listing. The simultaneous announcements from three separate biotech names in a single morning underscores the ongoing compliance pressure facing small-cap names in the sector.